Martin Daumer is the Director of the Sylvia Lawry Centre for MS Research. He is managing director of Trium Analysis Online GmbH (50% ownership).
Trium is a manufacturer of CTG monitoring systems. He is an Academic Editor for PeerJ and has invented the "free heel running pad".
Dr. Daumer has served on the scientific advisory board for the EPOSA study; has received funding for travel from ECTRIMS; serves on the editorial board of MedNous; is co-author with Michael Scholz on patents re: Apparatus for measuring activity (Trium Analysis Online GmbH), method and device for detecting a movement pattern (Trium Analysis Online GmbH), device and method to measure the activity of a person (Trium Analysis Online GmbH), co-Author with Christian Lederer of device and method to determine the fetal heart rate from ultrasound signals (Trium Analysis Online GmbH), author of method and device for detecting drifts, jumps and/or outliers of measurement values, coauthor of patent applications with Michael Scholz of device and method to determine the global alarm state of a patient monitoring system, method of communication of units in a patient monitoring system, and system and method for patient monitoring; serves as a consultant for University of Oxford, Imperial College London, University of Southampton, Charité Berlin, University of Vienna, Greencoat Ltd, Biopartners, Biogen Idec, Bayer Schering Pharma, Roche, and Novartis; and receives/has received research support from the EU-FP7, BMBF, BWiMi, and Hertie Foundation.
Christian Lederer has been employed by the SLCMSR during the conduct of th study. Gerhard Aigner has been employed by Trium Analysis Online GmbH during the conduct of the study. Nuridinow was employed by the SLCMSR during the conduct of the study. Bernd Grimm has been employed by the SLCMSR and declares that he has no competing interests.